The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
April 23, 2018
Copanlisib (Aliqopa) for Relapsed Follicular Lymphoma (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Copanlisib (Aliqopa) for Relapsed Follicular Lymphoma (online only)
April 23, 2018 (Issue: 1545)
The FDA has granted accelerated approval to copanlisib
(Aliqopa – Bayer), an intravenously administered
phosphatidylinositol 3-kinase (PI3K) inhibitor, for
treatment of adults with relapsed follicular lymphoma
who have received at least two...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.